A case of childhood high immunoglobulin M immunodeficiency syndrome combined with Talaromyces marneffei infection and active pulmonary tuberculosis

doi:10.19871/j.cnki.xfcrbzz.2024.06.011

Abstract

Abstract: High immunoglobulin M(HIGM) is a rare immune deficiency disorder caused by genetic mutations. Due to the compromised immune system, individuals are prone to various opportunistic infections and can develop the condition as infants. This case reports a 2-year and 8-month-old male child with HIGM immunodeficiency syndrome, who was diagnosed with the condition at another hospital due to recurrent pneumonia. He was later referred to our hospital for treatment after developing tuberculosis and lymph node tuberculosis. Despite anti-tuberculosis treatment, the patient continued to have fever and developed nausea and vomiting during hospitalization. A cerebrospinal fluid metagenomic analysis identified Talaromyces marneffei. Considering the intracranial infection by Talaromyces marneffei, we administered anti-tuberculosis and antifungal treatment along with immunoglobulin supplementation for immune support. The patient's temperature gradually decreased, and cerebrospinal fluid protein levels normalized. After completing the antifungal and anti-tuberculosis treatments, the patient received intravenous immunoglobulin every 3-4 weeks for immune support, along with clinical follow-up and monitoring of immunoglobulin levels. The patient's condition is currently stable with normal growth and development.

Key words: High immunoglobulin M immunodeficiency syndrome, Talaromyces marneffei infection, Active pulmonary tuberculosis, Child

CLC Number:

R521
R519

Zhao Chunyan, Song Chang, Li Qiang, Huang Aichun, Wei Xiaoying, Zeng Chunmei, Zhu Qingdong. A case of childhood high immunoglobulin M immunodeficiency syndrome combined with Talaromyces marneffei infection and active pulmonary tuberculosis[J]. Electronic Journal of Emerging Infectious Diseases, 2024, 9(6): 60-63.

References

[1] MAJID S, KIMURA N, LAM F, et al.Compound Heterozygosity in Hyper-IgM Syndrome Type 3: Case Report and Literature Review[J]. J Clin Immunol, 2024, 44(3): 64.
[2] MOAZZAMI B, YAZDANI R, AZIZI G, et al.Respiratory Complications in Patients with Hyper IgM Syndrome[J]. J Clin Immunol, 2019, 39(6): 557-568.
[3] DRABE CH, MARVIG RL, BORGWARDT L, et al.Case Report: Hyper IgM Syndrome Identified by Whole Genome Sequencing in a Young Syrian Man Presenting With Atypical, Severe and Recurrent Mucosal Leishmaniasis[J]. Front Immunol, 2020, 11: 567856.
[4] KIM D, SHIN JA, HAN SB, et al.Pneumocystis jirovecii pneumonia as an initial manifestation of hyper-IgM syndrome in an infant: A case report[J]. Medicine, 2019, 98(7): e14559.
[5] ROMANI L, WILLIAMSON PR, DI CESARE S, et al.Cryptococcal Meningitis and Post-Infectious Inflammatory Response Syndrome in a Patient With X-Linked Hyper IgM Syndrome: A Case Report and Review of the Literature[J]. Front Immunol, 2021, 12: 708837.
[6] KRISHNAN VP, TAUR P, PANDROWALA A, et al.X-Linked Hyper IgM Syndrome Presenting with Recurrent Tuberculosis-a Case Report[J]. J Clin Immunol, 2020, 40(3): 531-533.
[7] SIA JK, RENGARAJAN J.Immunology of Mycobacterium tuberculosis Infections[J]. Microbiol Spectr, 2019, 7(4):10.
[8] TURNER RD, CHIU C, CHURCHYARD GJ, et al.Tuberculosis Infectiousness and Host Susceptibility[J]. J Infect Dis, 2017, 216(suppl_6): S636-s643.
[9] GUO J, NING XQ, DING JY, et al.Anti-IFN-γ autoantibodies underlie disseminated Talaromyces marneffei infections[J]. J Exp Med, 2020, 217(12): e20190502.
[10] YAZDANI R, FEKRVAND S, SHAHKARAMI S, et al.The hyper IgM syndromes: Epidemiology, pathogenesis, clinical manifestations, diagnosis and management[J]. Clin Immunol, 2019, 198: 19-30.
[11] ALLEN RC, ARMITAGE RJ, CONLEY ME, et al.CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome[J]. Science, 1993, 259(5097): 990-993.
[12] VIAL G, GENSOUS N, DUFFAU P.The CD40-CD40L axis: Current and future implications in clinical immunology[J]. Rev Med Interne, 2021, 42(10): 722-728.
[13] GRAF D, KORTHäUER U, MAGES HW, et al. Cloning of TRAP, a ligand for CD40 on human T cells[J]. Eur J Immunol, 1992, 22(12): 3191-3194.
[14] CHANDOLA S, PRABHAKAR P, SETH R, et al.Intramural Duodenal Hematoma in a Case of Hyper IgM Syndrome[J]. J Pediatr Hematol Oncol, 2024, 46(2): 104-105.
[15] FAN H, HUANG L, YANG D, et al.Respiratory infections in X-linked hyper-IgM syndrome with CD40LG mutation: a case series of seven children in China[J]. BMC Pediatr, 2022, 22(1): 675.
[16] SUPPARATPINYO K, KHAMWAN C, BAOSOUNG V, et al.Disseminated Penicillium marneffei infection in southeast Asia[J]. Lancet, 1994, 344(8915): 110-113.
[17] HE L, MEI X, LU S, et al.Talaromyces marneffei infection in non-HIV-infected patients in mainland China[J]. Mycoses, 2021, 64(10): 1170-1176.
[18] PRUKSAPHON K, NOSANCHUK JD, RATANABANANGKOON K, et al.Talaromyces marneffei Infection: Virulence, Intracellular Lifestyle and Host Defense Mechanisms[J]. J Fungi (Basel), 2022, 8(2): 200.
[19] CHEN Z, LUO XL, LI WQ, et al.Talaromyces Marneffei Infection in an HIV-Negative Patient in a Non-Endemic Area: a Case Report and Literature Review[J]. Clin Lab, 2023, 69(9).
[20] 李逸攀, 宋璐, 史延斌, 等. 艾滋病合并马尔尼菲蓝状菌感染患者胸部CT特征分析[J/CD]. 新发传染病电子杂志, 2023, 8(1): 35-38.
[21] YANG Q, HAN J, SHEN J, et al.Diagnosis and treatment of tuberculosis in adults with HIV[J]. Medicine (Baltimore), 2022, 101(35): e30405.
[22] GLANZMANN B, UREN C, DE VILLIERS N, et al.Primary immunodeficiency diseases in a tuberculosis endemic region: challenges and opportunities[J]. Genes Immun, 2019, 20(6): 447-454.
[23] QAMAR N, FULEIHAN RL.The hyper IgM syndromes[J]. Clin Rev Allergy Immunol, 2014, 46(2): 120-130.
[24] CORONADO-HERNáNDEZ KG, CAMPOS-TéLLEZ HH, CORTéS-GRIMALDO RM, et al. Hyper-IgM syndrome with early liver involvement[J]. Rev Alerg Mex, 2023, 69(4): 214-219.
[25] AL-DHEKRI H, AL-SUM Z, AL-SAUD B, et al.Successful outcome in two patients with CD40 deficiency treated with allogeneic HCST[J]. Clin Immunol, 2012, 143(1): 96-98.
[26] MENG X, YANG B, SUEN WC.Prospects for modulating the CD40/CD40L pathway in the therapy of the hyper-IgM syndrome[J]. Innate Immun, 2018, 24(1): 4-10.